In contrast, the role of v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2), the preferred dimerization partner of EGFR, remains poorly understood. Here, using a mouse model with inactivation of Erbb2 in pancreatic acinar cells, we found that Erbb2 is dispensable for inflammation-and KRas G12D -induced development of ADM and PanIN. A mathematical model of EGFR/ERBB2-KRAS signaling, which was calibrated on mouse and human data, supported the observed roles of EGFR and ERBB2. However, this model also predicted that overexpression of ERBB2 stimulates ERBB/KRAS signaling; this prediction was validated experimentally. We conclude that EGFR and ERBB2 differentially impact ERBB signaling during PDAC tumorigenesis, and that the oncogenic potential of ERBB2 is only manifested when it is overexpressed. Therefore, the level of ERBB2, not only its mere presence, needs to be considered when designing therapies targeting ERBB signaling.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with a 5-year survival rate of about 7%. This poor prognosis is due to resistance to therapy and late diagnosis 1 , which prompts the need for better characterization of the molecular mechanisms that promote and drive PDAC formation.
Molecular and histological studies provided evidence that pancreatic intraepithelial neoplasia (PanIN) are preinvasive lesions of PDAC. PanIN arise from acinar cells that undergo inflammation-induced acinar-to-ductal metaplasia (ADM) 2, 3 , a process leading to repression of the acinar gene expression program and the acquisition of a duct-like phenotype 4, 5 . PanIN are genetically characterized by the presence of several mutations in tumor suppressors and proto-oncogenes 1, 6 . The most prevalent mutation is an activating mutation in the KRAS oncogene (KRAS
G12D
) found in more than 90% of PDAC; this mutation is considered the initiating event of pancreatic cancer, whereas mutations in other oncogenes or tumor suppressors are required for tumor progression 7 . The tyrosine kinase receptor EGFR/ERBB1 plays an essential role in pancreatic tumorigenesis. In its absence, oncogenic KRAS G12D is unable to drive PanIN development. Yet, its role seems more important in the early phases of the disease than in PDAC progression 8, 9 . Other studies suggest that ERBB2, the preferred dimerization partner of EGFR 10, 11 , is also involved in PDAC 12, 13 . Thus, acinar overexpression of ERBB2 leads to mild pancreatic inflammation and ADM 12 , whereas expression of a mutated active form of Erbb2 (a mutation usually not found in PDAC) in mouse embryonic pancreas accelerates the development of PanIN after birth 13 . Unlike breast cancer where ERBB2 is frequently amplified and plays an important role in tumor progression, ERBB2 amplification is detected at low frequency in PDAC 14 . This contrasts with the high number of PDAC cases (about 50%) that show a detectable level of ERBB2 expression, and with the high expression of ERBB2 correlating with a higher grade of cellular atypia 15 . In addition, in a mouse model of PDAC, phosphorylation of ERK, a kinase downstream of EGFR and ERBB2, correlates better with the expression of ERBB2 than with that of EGFR 6 . Altogether, these observations suggest that ERBB2 plays a role in PDAC tumorigenesis. However, the requirement of ERBB2 in this process has not been investigated.
In the present work, we used an Erbb2 deletion mouse model and mathematical modeling to investigate the role of ERBB2 in PDAC initiation. We find that the function of ERBB2 in pancreatic tumorigenesis differs from that of EGFR and is strongly dependent on its level of expression.
Results

ERBB2 is dispensable for PanIN formation. Egfr deletion in pancreatic acinar cells prevents PanIN
and PDAC formation in mouse models expressing oncogenic KRAS 8, 9 . Since ERBB2 is the preferred dimerization partner of EGFR 10, 11 , we hypothesized that ERBB2 is also important for pancreatic tumorigenesis. As a first step to address this question, we characterized the ERBB2 expression pattern in wild-type (WT) mice and in mice expressing oncogenic KRAS G12D in acinar cells (ElaC ER Kras G12D mice), in the absence or in the presence of cerulein-induced pancreatitis (Fig. 1A,B and Supplementary Fig. S1 ). In WT and ElaC ER Kras G12D pancreas, in the absence of inflammation, ERBB2 was detected at the basolateral domains of the duct cells (dotted circle); ERBB2 labeling in acini was not membrane-associated and was considered non-specific. When WT mice received acute (W1) or chronic (W3 and W9) cerulein treatment, ERBB2 expression was ectopically induced in metaplastic acinar cells that had strongly reduced levels of amylase (late ADM; white arrows). ERBB2 expression in ElaC ER Kras G12D mice treated acutely with cerulein was similar to that in WT mice, with ERBB2 being detected in acinar-derived duct-like structures (white arrows). Moreover, after chronic treatment, ERBB2 expression was maintained in early and late PanIN stages (yellow arrows). Therefore, we concluded that ERBB2 is expressed in precancerous lesions of PDAC.
Next, to investigate the impact of Erbb2 deletion on neoplastic progression, we generated mice bearing a conditional deletion of Erbb2 in acinar cells ( (Fig. 2B ). These numbers increased with the duration of cerulein treatment ( Fig. 2C-D) . We verified that Erbb2 was deleted in ElaC ER Erbb2 KO and ElaC ER Erbb2 KO Kras G12D mice: ERBB2 immunolabeling confirmed the absence of ERBB2 expression in ADM and PanIN in the pancreas after cerulein treatment ( Fig. 3 and Supplementary Fig. S2 ). The deletion was partial since quantification of Erbb2 deletion indicated a 6-fold reduction in the number of cells expressing ERBB2 in ElaC ER Erbb2 KO Kras G12D pancreata compared to ElaC ER Kras G12D pancreata after 9 weeks of cerulein treatment ( Supplementary Fig. S3A ). In contrast, an identical proportion of cells expressed EGFR in these pancreata ( Supplementary Fig. S3B Supplementary Fig. S3C ). These results indicated that, at the histological level, Erbb2 deletion does not impact the presence or frequency of ADM and PanIN lesions.
ERBB2-positive and ERBB2-deficient PanIN share the same molecular features. To investigate whether ADM and PanIN formed from ERBB2-positive and ERBB2-deficient acinar cells were similar at the molecular level, we first performed immunolabeling for SOX9 and CK19, two ADM and PanIN markers 16 . After induction of acute (W1) or chronic (W3) pancreatitis, SOX9 and CK19 expression was detected in metaplastic KO panel shows that the ERBB2 labeling is cytoplasmic and non-specific. Expression of the metaplastic markers CK19 and SOX9 is observed in ductal cells (white arrows) which also express ERBB2 as well as in duct-like cells and PanIN. Scale bars = 50 μm.
www.nature.com/scientificreports www.nature.com/scientificreports/ acini of WT and ElaC ER Erbb2 KO mice (Fig. 3 ). SOX9 and CK19 were also expressed in PanINs of ElaC ER Kras G12D and ElaC ER Erbb2 KO Kras G12D mice treated for 1 or 3 weeks with cerulein ( Fig. 3 and Supplementary Fig. S2 ). Collagen deposition and immune cell infiltration were analyzed: no difference was observed in the absence or presence of ERBB2 ( Supplementary Fig. S4 ).
The lack of detectable effect of Erbb2 deletion on ADM and PanIN formation, prompted us to assess whether increased expression or activity of other ERBB family members would compensate for Erbb2 loss. Since EGFR and ERBB3 reportedly promote PDAC tumorigenesis 8, 9, 17 , we performed immunolabeling for EGFR, P-EGFR Y845 (as a surrogate of EGFR activity) and ERBB3. Their expression was similar in ADM and PanIN lesions present in the different genotypes, irrespective of the presence or absence of ERBB2 (Fig. 4A, Supplementary Figs . S5 and S6). Thus, we conclude that Erbb2 deletion does not significantly affect the expression or activity of other ERBB family members. Yet, the presence of the other ERBB proteins might be sufficient to compensate for the loss of ERBB2.
Moreover, the RAS/MAPK and PI3K/AKT pathways are normally activated by ERBB2 and are involved in the formation and progression of pancreatic neoplastic lesions [18] [19] [20] . In acute or chronic cerulein treatment (W1, W3 or W9), ERK phosphorylation, a marker of MAPK pathway activity, was observed in a limited number of metaplastic acini of WT mice whereas high levels of ERK phosphorylation were detected in PanIN in ElaC ER Kras G12D pancreas ( Fig. 4B and Supplementary Fig. S7 ). Supplementary Fig. S7 ). The same conclusions were drawn when analysing the AKT pathway: high activity was observed in the pancreas of the various genotypes using a P-AKT T308 antibody ( Fig. 4B and Supplementary Fig. S7 ) or a P-AKT S473 antibody (data not shown). This indicates that Erbb2 loss does not significantly perturb the activity of the RAS/MAPK and PI3K/AKT pathways.
The differential roles for EGFR and ERBB2 in mouse ADM and PanIN development result from signaling properties of the ERBB pathway. Despite that ERBB2 is the preferred dimerization partner of EGFR, its expression is dispensable for ADM and PanIN formation, in contrast to EGFR. To understand this counter-intuitive observation, we investigated how EGFR and ERBB2 control the dynamics of signaling initiation by building an experiment-based mathematical model. This model represents a regulatory network composed of interacting KRAS, EGFR and ERBB2 (Fig. 5A ). The interactions consist of direct or indirect functional links, namely protein-protein and epistatic relationships that have been experimentally validated 6, 8, 9, 12, [21] [22] [23] [24] [25] . Indeed, EGFR and ERBB2 monomers can reversibly form EGFR:EGFR homodimers, ERBB2:ERBB2 homodimers or EGFR:ERBB2 heterodimers. These dimers participate in the transcriptional regulation of KRAS, EGFR and ERBB2, and can activate KRAS. KRAS can stimulate transcription of EGFR and ERBB2 6, 8, 9, 16, 21, 22, 24, 26 . The mathematical model consists of a set of kinetic equations describing each interaction in the network, namely the temporal evolution of the expression levels of each network component. It includes mRNA and protein forms of EGFR, ERBB2 and KRAS, and considers inactive (GDP-bound) and active (GTP-bound) KRAS, as well as the monomers, homodimers and heterodimers of EGFR and ERBB2. In the model, ERBB signaling activity is then defined by the sum of the protein expression levels of EGFR and ERBB2 homodimers, EGFR:ERBB2 heterodimers, and active forms of KRAS that are present in a given condition (Supplementary Information). The model's quantitative assumptions, the equations and the parameter values used in the simulations are described in Supplementary Information.
First, we calibrated the mathematical model based on the expression levels of Egfr, Erbb2 and Kras mRNAs measured in the pancreas of WT mice, in the absence or in the presence of acute cerulein treatment (W1), which induces ADM and increased expression of Egfr, Erbb2 and Kras mRNAs. Protein expression levels were estimated from literature data (Supplementary Table 4 and ref. 27 ). When introducing in the model the measured Erbb2 expression levels in normal and cerulein-treated condition, the model faithfully predicted the corresponding expression of Egfr and Kras (Fig. 5B) . The model was then used to simulate the impact of variations of Egfr and Erbb2 mRNA expression on the dynamics of ERBB signaling defined as above. Our model predicted that with or without cerulein treatment, a decrease in Egfr mRNA, starting from the control value (blue vertical line in Fig. 5C ) strongly affects ERBB signaling activity, while a decrease of Erbb2 mRNA does not (Fig. 5C, red curves) . This prediction is robust since the predicted effects of Egfr and Erbb2 mRNAs on ERBB signaling are maintained when we model a heterogeneous cell population by introducing 50% of uniform random variations around the basal value of each parameter ( Fig. 5C : each black dot corresponds to the simulation for one cell in the heterogeneous population). We concluded that a quantitative mathematical model of the interactions between KRAS, EGFR and ERBB2, and calibrated on mouse expression data, suggests that EGFR is critical for ERBB signaling activity in the studied context, while ERBB2 is dispensable. This is in line with their roles in ADM and PanIN development as shown in the present work for ERBB2 and by others for EGFR 8 .
Modeling ERBB signaling suggests that ERBB2 is dispensable for development of human PDAC.
Taking advantage of the robustness of the model and of its ability to faithfully predict ERBB signaling in mice, we next applied it to human pancreas. The structure of the EGFR/ERBB2/KRAS network (Fig. 5A ) had been experimentally validated in mice. In humans, we validated the network by verifying whether expression of EGFR, ERBB2 and KRAS mRNA was positively correlated in human PDAC (Fig. 6D) . The PDAC cohort (n = 178) of TCGA was used as a source of data. By comparing the 50 PDAC samples from the cohort that show the highest expression of either EGFR, ERBB2 or KRAS, with the 50 samples that have the lowest expression of the same component, we found that high mean expression of one of the three genes correlated with high mean expression of the two others; similarly, low mean expression of one of the three genes correlated with low mean expression of the two others. This correlation was extended to the mRNA levels of ERBB3 and SOX9, two other components of the ERBB pathway (Fig. 6D ) 16 . However, we have not considered ERBB3 as a dimerization partner for EGFR and ERBB2 in our mathematical model, since the ERBB3 ligands NRG1 and NRG2 are not, or marginally, expressed Fig. S8A ) 28 , in human PDAC ( Supplementary Fig. S8B ), and in mouse pancreas ( Supplementary Fig. S8C ). In addition, phosphorylation of ERBB3 was not detected in mouse pancreas ( Supplementary Fig. S8D ). Together, these results indicate that ERBB3 is not active in the pancreas.
We next recalibrated the mathematical model on the expression levels of human ERBB2, EGFR and KRAS mRNAs detected in three different PDAC conditions (RNASeq data from TCGA): (i) in all tumors (n = 178), (ii) in the 50 tumors with lowest or (iii) highest expression of ERBB2 mRNA. This recalibration on human data was performed by modifying only the transcription rates of EGFR, ERBB2 and KRAS (see Supplementary Information). As in mice, the protein expression levels in human conditions were estimated from literature data (Supplementary Information). By introducing in the model the mean ERBB2 expression values measured in all tumors, the model faithfully predicted the measured expression of EGFR and KRAS (Fig. 6A, black bars) . Similarly, when introducing in the model the mean ERBB2 values measured in the 50 PDAC samples that had the lowest ERBB2 expression (Fig. 6A, blue bars) or the ERBB2 values measured in the 50 samples with the highest ERBB2 expression (Fig. 6A, red bars) , the model faithfully predicted the corresponding expression of EGFR and KRAS. This result showed that the model was properly calibrated with human data to enable simulation of EGFR or ERBB2 variations.
We then simulated the steady-state levels of ERBB signaling activity, defined as above, as a function of the concentration of EGFR and ERBB2 mRNAs (Fig. 6B, red curves) . The model showed, like in mice, that reduction in EGFR starting at the control value (blue vertical line in Fig. 6B ) reduces ERBB signaling while reduced ERBB2 expression does not affect ERBB signaling. As in mice, in a heterogeneous patient PDAC population, the model predicted a robust network dynamics even in the presence of 50% of random fluctuations of the parameter values (Fig. 6B, black dots) .
In addition to having robust network dynamics towards random fluctuations in parameter values (Fig. 6B) , the model exhibits, with 50% of random fluctuation on parameter values, a level of heterogeneity in EGFR, ERBB2 and KRAS mRNA expression similar to that in the human PDAC (Fig. 6C) . This indicates that fluctuations in the network dynamics are similar in the model and in the human PDAC condition.
In conclusion, our analysis suggests that in human pancreas at PDAC stage, like in mouse pancreas in precancerous lesions, EGFR, but not ERBB2, is critical for ERBB signaling. www.nature.com/scientificreports www.nature.com/scientificreports/ Transcription and translation rates of EGFR and ERBB2 are critical for ERBB signaling. In silico modeling, based on human PDAC condition, enables to determine why ERBB2 is dispensable for ERBB signaling by analysing the parameters that are critical in the network. To address this question, we plotted the steady-state levels of ERBB signaling activity as a function of ERBB2 (Supplementary Fig. S9 ) or EGFR mRNA levels ( Supplementary Fig. S10 ) in the presence of a ten-fold increase or decrease of each parameter value. These analyses predicted that reducing ERBB2 mRNA has no impact on signaling except if the transcription (T EGFR ) and translation (V SEGFR ) rates of EGFR are very low ( Supplementary Fig. S9A,C) . All other parameters characterizing ERBB2, EGFR and KRAS expression, degradation, dimerization and activity have little or no influence on the effect of ERBB2 mRNA levels on ERBB signaling ( Supplementary Fig. S9B,D-Q) . In parallel, simulating a decrease in EGFR mRNA levels strongly reduces ERBB signaling except if the transcription (T ERBB2 ) and translation (V SERBB2 ) rates of ERBB2 are very high, or if the homodimerization rate (k ASS2 ) of ERBB2 strongly increases ( Supplementary Fig. S10A,D,G) . Other parameter values do not affect the function of EGFR. In other terms, expression of ERBB2 would only compensate for low EGFR levels when ERBB2 expression or homodimerization is high.
Finally, as observed experimentally 8 , a rise in the expression level of EGFR is predicted to increase the activity of ERBB signaling. Rising ERBB2 expression is also predicted to stimulate ERBB signaling, but only at expression levels that are higher than physiological levels, i.e. when ERBB2 is overexpressed. These predictions fit with published experimental data showing how ERBB2 and EGFR promote development of precancerous lesions 12, 24, 25 . 
ERBB2 overexpression stimulates ERBB signaling activity.
To experimentally validate our mathematical model in the presence of increased expression of ERBB2, PANC1 and MiaPaCa-2 cells were infected with empty or mErbb2 lentiviral vectors ( Fig. 7 and Supplementary Fig. S11 ). ERBB2 overexpression was associated with an increase of P-ERBB2 Y1248 , P-EGFR Y1068 and P-EGFR Y1173 in PANC1 cells, and an increase of P-ERBB2
Y1248
and P-EGFR Y1068 in MiaPaCa-2 cells. KRAS-GTP/KRAS ratio also increased in PANC1 cells, which supported that ERBB2 signaling was stimulated. We concluded that ERBB2 overexpression leads to an increased ERBB signaling activity in PANC1 cells, as predicted by our mathematical model.
Discussion
EGFR and ERBB2 are often expressed or overexpressed in human PDAC [29] [30] [31] [32] , and their overexpression is frequently correlated 33 . In human PDAC cell lines, EGFR is known to stimulate proliferation 9 , and in mouse models with oncogenic KRAS G12D expression, deletion of Egfr impedes PanIN and PDAC formation 8, 9 . A similar mouse model with deletion of Erbb2 has not been generated. However, overexpression of ERBB2 in mouse acinar cells leads to chronic pancreatic inflammation and increased KRAS expression and activity 12 . In this system, despite the presence of inflammation, PanIN and PDAC are not observed, likely because KRAS is not mutated. Recently, ERBB2, in conjonction with oncogenic KRAS G12D , was shown to promote formation of pancreatic neoplastic lesions 13 . However, a mutant form of activated rat ERBB2 was used, and, unlike in humans, its expression started in embryonic pancreatic progenitors which are notoriously overresponsive to oncogenic stress. Also, the selected ERBB2 mutation has to our knowledge not been found in human PDAC. Recently, ERBB2 amplification and gain-of-function mutations have been identified in human PDAC patients, and mutations of ERBB2 and KRAS co-occur. Cell culture studies revealed that inhibition of ERBB2 in PDAC cell lines overexpressing ERBB2 represses proliferation and invasion 34 . Finally, heterogeneous expression of EGFR was detected in a mouse model of PDAC with Kras G12D and Tp53 R172H mutations, whereas ERBB2 expression and ERK activation were elevated and homogeneous in PanIN, PDAC and metastases 6 . Since ERBB2 is the preferred dimerization partner of EGFR 10, 11 , these data suggest that ERBB2 plays an important role in PanIN/PDAC formation. Here, we explored the role of ERBB2 in development of ADM and PanIN and in ERBB signaling. We surprisingly found that deletion of Erbb2 does not impact ADM and PanIN formation in mice. In agreement with our experimental observations, our mathematical model, which considers dimerization of EGFR and ERBB2 and activation of KRAS, predicts that overexpression of EGFR or ERBB2 promotes ERBB signaling, while downregulation of EGFR deletion decreases ERBB signaling. The mathematical model also predicts that downregulation ERBB2 does not impact ERBB signaling, except if it is overexpressed. This prediction fits with the fact that ERBB2 is a tyrosine kinase receptor that only homodimerizes when it is overexpressed, as was shown in breast cancer 35 . In other terms, its oncogenic potential is only achieved when overexpressed, in contrast to EGFR. Our in vitro experiments using PANC1 cells are in agreement with our mathematical model. We acknowledge that in these experiments the increased activity of ERBB signaling is modest following ERBB2 overexpression. However, this overexpression is obtained by lentiviral infection and only reaches 2 to 2.5-fold; in our model, this corresponds to the onset of ERBB2-induced stimulation of ERBB signaling, suggesting that larger overexpression will lead to an even higher stimulation of signaling.
Transcript levels of EGFR, ERBB2 and KRAS are heterogeneous in the human PDAC samples from TCGA (Fig. 6C ). The mathematical model for a heterogeneous cell population indicates that 50% of random variation around the basal value of each parameter reproduces tumor heterogeneity. It further indicates that stochastic gene expression in ERBB signaling may be a source of heterogeneity in PDAC and, as a consequence, could cause heterogeneous response to therapy.
The core network composed of EGFR, ERBB2 and KRAS described here, is regulated by other genes. SOX9 activates the ERBB pathway, resulting in PDAC initiation 16 , and KRAS can activate a SRC/PEAK1/ERBB2 amplification loop in PDAC 36 . The impact of the core network regulators is taken into account in the model, namely in the parameters that determine the synthesis and degradation rates of EGFR, ERBB2 and KRAS.
In conclusion, our data show that deletion of Erbb2 in acinar cells does not affect ERBB signaling activation during ADM and/or PanIN development, unlike deletion of Egfr. In contrast, increased expression of ERBB2 stimulates ERBB signaling. Therefore, EGFR and ERBB2 differentially impact ERBB signaling during pancreatic cancer tumorigenesis, highlighting the need to consider patient's specific characteristics of ERBB signaling to optimize therapeutic treatment.
Materials and methods
Mouse experimentation. Elastase Immunohistochemistry and immunofluorescence. Pancreata were fixed for 4 or 6 hours in 4% paraformaldehyde at 4 °C and then embedded in paraffin. Antigen retrieval was performed in a microwave oven by incubating 6 µm tissue sections in 10 mM citrate buffer (pH 6) for 10 minutes (or in PreTreatment Module, Lab Vision, for 2 hours). Sections were then permeabilized in PBS/0.3% Triton X-100 (Sigma) buffer for 5 minutes and blocked with PBS/3% low-fat milk/10% bovine serum/0.3% Triton X-100 for 45 minutes at room temperature. . ERBB2 overexpression partially impacts ERBB signaling activity. Representative immunoblots of proteins extracted from PANC1 cells infected with empty or mErbb2 lentiviruses. Levels of ERBB2, EGFR and their phosphorylated forms, as well as the KRAS-GTP/KRAS ratio, were quantified; they increased significantly after mErbb2 lentiviral infection. Fold inductions are mentioned as mean +/− SD; ns, p > 0.05. Phosphorylated and nonphosphorylated forms of ERBB2 and EGFR were detected on the same blots. Consequently, HSC70 loading controls were the same. Blots were cropped and full-lengt blots are avaible in Supplementary Figs . S13 to S15.
Primary antibodies were diluted in blocking buffer and incubated overnight at 4 °C (See Supplementary  Table 1) . Secondary antibodies and streptavidin-POD conjugate (1/1000) were diluted in PBS/10% bovine serum/0.3% Triton X-100 for 1 hour at 37 °C. Pictures were taken using a Cell Observer Spinning Disk confocal microscope (Zeiss, Zaventem, Belgium) after immunofluorescence labelling, or with a Mirax imaging system (Zeiss) after immunohistochemical staining.
Cell culture experiments. PANC1 and MiaPaCa-2 cell lines were grown in DMEM (Lonza, Leusden, Netherlands) supplemented with fetal bovine serum (FBS) 10% (Merck, Darmstadt Germany), sodium pyruvate (1 mM) (Gibco ™ , Waltham, MA, USA), penicillin-streptomycin 1% (Gibco ™ ) and amphotericin B 1% (Gibco ™ ). For MiaPaCa-2 cells, horse serum 2.5% (Gibco ™ ) was added to the medium. HEK-293T cells were grown in DMEM (Lonza) supplemented with FBS 10% (Merck), penicillin-streptomycin 1% (Gibco ™ ) and amphotericin B 1% (Gibco ™ ). Lentiviral particles were obtained by calcium phosphate-mediated transfection of HEK-293T. HEK-293T cells were seeded and transfected with plasmids encoding proteins involved in viral packaging (pRSV-REV, pCMV-dR8.2 dvpr and pCMV-VSV-G) as well as pLenti-PGK-Empty or pLenti-PGK-mErbb2. These plasmids and their constructions are detailed in Supplementary Information. Lentiviruses were collected, filtered and concentrated with Lenti-X ™ Concentrator (Clontech, Mountain View, CA, USA). Concentrated lentiviruses were added to target cells (PANC1) that were selected with hygromycin B (Sigma) at 400 µg/ml (MiaPaCa-2) or 600 µg/ ml (PANC1) for 2 weeks. For Western Blot experiments and KRAS pull-down assay, PANC1 cell lines were collected 48 hours after plating. Detailed experimental protocols about Western Blot and KRAS pull-down assay can be found in Supplementary Information.
RNA extraction and analysis. Total RNA was isolated from fragments of pancreas using Trizol (Invitrogen, Life technologies). cDNA was synthesized using MMLV reverse transcriptase (Invitrogen, Life technologies) according to manufacturer's protocol. Gene expression was quantified by RT-qPCR using Kapa SYBR Fast 2X Universal Master Mix (Sopachem). mRNA levels were normalized with the geometric mean between Gapdh and 18S. RNASeq data and statistical analysis. RNASeq data were from the PDAC cohort in the The Cancer Genome Atlas (TCGA) database (http://firebrowse.org/). We normalized the mRNA expression levels to the expression of ERBB2 mRNA. Data are means ± SD. Significance was assessed by Student t-test or by Student t-test with Benjamini-Hochberg corrections considering the entire transcriptome (Fig. 6) .
Mathematical model. The mathematical model is defined by a set of kinetic equations describing the temporal evolution of the mRNA and protein expression levels of EGFR, ERBB2 and KRAS. The mathematical model with the kinetic equations and the parameter values are described in Supplementary Information. Numerical simulations were performed with XPPAUTO (http://www.math.pitt.edu/~bard/xpp/xpp.html) and Matlab.
